文献速递骨软组织肉瘤与黑色素瘤

转移性葡萄膜黑色素瘤接受程序性细胞死亡-1或PD-1/细胞毒性T淋巴细胞抗原-4联合抑制治疗的预后因素与结局

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
PubMed 文献 · Eur J Cancer · 2017-06-22

该研究纳入来自20家德国皮肤癌中心的96例转移性葡萄膜黑色素瘤患者,分析PD-1抑制剂单药或PD-1抑制剂联合伊匹木单抗治疗的结局。单药组中心确认缓解率为4.7%,帕博利珠单抗组中位OS 14个月,纳武利尤单抗组10个月(p=0.765)。多因素分析显示ECOG体能状态、LDH升高、CRP升高和相对嗜酸性粒细胞计数<1.5%为独立不良预后因素。

要点

  • PD-1抑制剂单药治疗转移性葡萄膜黑色素瘤的中心确认缓解率为4.7%。
  • 帕博利珠单抗组中位OS 14个月,纳武利尤单抗组10个月,两组差异无统计学意义(p=0.765)。
  • ECOG体能状态、LDH升高、CRP升高和相对嗜酸性粒细胞计数<1.5%为独立不良预后因素。

核心结论

  • 血液标志物可预测接受免疫检查点阻断治疗的转移性葡萄膜黑色素瘤患者的生存。
  • 血清LDH和CRP水平正常以及相对嗜酸性粒细胞计数较高可能有助于识别预后较好的患者。

研究设计与样本

  • 研究纳入来自20家德国皮肤癌中心的96例转移性葡萄膜黑色素瘤患者,接受PD-1抑制剂单药或PD-1抑制剂联合伊匹木单抗治疗。
  • 采用多因素Cox回归和二元逻辑回归分析临床及血液参数与总生存或治疗缓解的关联。

主要发现

  • 86例患者接受PD-1抑制剂单药治疗(帕博利珠单抗54例,纳武利尤单抗32例),中心确认缓解率为4.7%。
  • 帕博利珠单抗组中位OS为14个月,纳武利尤单抗组为10个月(p=0.765)。
  • 15例患者接受联合免疫检查点阻断治疗,其中2例观察到部分缓解,该组中位OS未达到。
  • 多因素Cox回归识别ECOG体能状态(p=0.002)、血清LDH升高(p=0.002)、CRP升高(p=0.001)和相对嗜酸性粒细胞计数<1.5%(p=0.002)为不良生存的独立风险因素。
  • CRP和LDH升高且相对嗜酸性粒细胞计数<1.5%的患者疾病进展和死亡风险最高(p=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uveal melanoma (UM) is an ocular malignancy with high potential for metastatic spread. In contrast to cutaneous melanoma, immunotherapy has not yet shown convincing efficacy in patients with UM. Combined immune checkpoint blockade with checkpoint programmed cell death-1 (PD-1) and checkpoint cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibition has not been systematically assessed for UM to date. PATIENTS AND METHODS: Patients with metastatic UM treated with either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) were included from 20 German skin cancer centres. Records from 96 cases were analysed for treatment outcomes. Clinical and blood parameters associated with overall survival (OS) or treatment response were identified with multivariate Cox regression and binary logistic regression. RESULTS: Eighty-six patients were treated with PD-1 inhibitors only (n = 54 for pembrolizumab, n = 32 for nivolumab) with a centrally confirmed response rate of 4.7%. Median OS was 14 months for pembrolizumab-treated and 10 months for nivolumab-treated patients (p = 0.765). Fifteen patients were treated with combined immune checkpoint blockade with partial response observed in two cases. Median OS was not reached in this group. Multivariate Cox regression identified Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.002), elevated serum levels of lactate dehydrogenase (LDH) (p = 0.002) and C-reactive protein (CRP) (p = 0.001), and a relative eosinophil count (REC) <1.5% (p = 0.002) as independent risk factors for poor survival. Patients with elevated CRP and LDH and a REC <1.5% were at highest risk for disease progression and death (p = 0.001). CONCLUSIONS: Blood markers predict survival in metastatic UM treated with immune checkpoint blockade. Normal serum levels of LDH and CRP and a high REC may help identify patients with better prognosis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Heppt MV, Heinzerling L, Kähler KC, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017. PMID: 28648699. doi:10.1016/j.ejca.2017.05.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。